Search

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Apply to be a Master Class mentor

Applications closed on July 15, 2024. There are two types of Master Class mentor: junior mentor and senior mentor. Before you apply, make sure you've read and understood the relevant eligibility criteria.

HemAffairs

HemAffairs holds your monthly dose of policy, regulatory and pharma news with impact on hematology in Europe. We also keep you abreast of relevant publications and events to keep an eye on. Enjoy the read!

EHA - Access to Medicine

Dec 27 2013

By reporting the unavailability of hematology medicine you are strengthening our efforts to improve patients' access to medicine across Europe. REPORT NOW

EBAH Certified Meetings

In this page, you will find hematology-related meetings which are either EBAH-certified or from partners of EHA. You can choose to see meetings per year or category in the menus below.

Report VIRTUAL EHA-SWG Scientific Meeting on Immunotherapy

Nov 27 2020 Posted in Meeting reports Tagged Immunotherapy

This scientific meeting was organized together with the EHA Scientific Working Group on Immune Therapies for Hematological Disorders.

CRTH – reflections on a unique learning experience

Mar 11 2021

CRTH (Clinical Research Training in Hematology) is a 9-month long unique training and mentoring experience focused on clinical research in Europe, with a global scope.